IPO
Filter News
Found 17,227 articles
-
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)-April 5, 2024
4/5/2024
Curis, Inc. today announced that on April 1, 2024, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 8,550 shares.
-
Cartesian Therapeutics Announces New Employment Inducement Grants
4/4/2024
Cartesian Therapeutics, Inc. today announced the granting of inducement awards to four new employees. On April 1, 2024, the Company issued to each of these employees an option to purchase shares of the Company’s common stock with an exercise price of $0.5601, the closing trading price of the Company’s common stock.
-
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/4/2024
Replimune Group, Inc. today announced the grant of inducement equity awards to Carolyn Trott, the Company’s newly appointed Senior Vice President, Quality Assurance.
-
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
4/4/2024
Allarity Therapeutics, Inc. today announced the implementation of a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20 (the “Reverse Stock Split”).
-
Bionano Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4/4/2024
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 8,733,626 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 8,733,626 shares of its common stock at an offering price of $1.145 per share of common stock.
-
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 4, 2024
4/4/2024
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 35,000 shares of its common stock to four new employees.
-
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
4/3/2024
Equillium, Inc. today announced that on April 1, 2024, the Compensation Committee of Equillium’s Board of Directors granted an inducement award consisting of a nonstatutory stock option to purchase 10,000 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan.
-
Obsidian Therapeutics Announces Oversubscribed $160.5 Million Series C Financing to Drive OBX-115 Clinical Development
4/3/2024
Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a significantly oversubscribed $160.5 million Series C financing with a top-tier syndicate of life science investors led by new investor, Wellington Management.
-
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
4/2/2024
Melt Pharmaceuticals, Inc. today announced the completion of its Series B Preferred Stock financing of approximately $24 million from new and existing investors at a pre‑money valuation that increased nearly 150% from the pre-money valuation for Melt’s Series A Preferred Stock.
-
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4/1/2024
Biora Therapeutics, Inc today announced that it has entered into definitive agreements for the purchase and sale of 5,454,548 shares of the Company’s common stock at an offering price of $1.10 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.
-
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 1, 2024
4/1/2024
Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company.
-
Applied UV, Inc. Announces Closing of $2.76 Million Registered Direct and Private Placement
4/1/2024
Applied UV, Inc. (NASDAQ: AUVI) (the “Company”), a leader in smart building technology solutions, today announced the closing of its previously announced registered direct offering and concurrent private placement with institutional investors.
-
Continuing 2024’s biotech initial public offering rally, Boundless Bio will debut Thursday on the Nasdaq with the proceeds used to advance its pipeline of extrachromosomal DNA cancer assets.
-
Boundless Bio Announces Pricing of Initial Public Offering
3/27/2024
Boundless Bio, Inc. (Nasdaq: BOLD), a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at an initial public offering price of $16.00 per share.
-
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)
3/25/2024
Allarity Therapeutics, Inc. today announced that the Company has been granted a formal extension until April 24, 2024 to regain compliance under Nasdaq Listing Rules 5550(a)(2) (the “Bid Price Rule”) and 5550(b)(1) (the “Equity Rule”) or any of the alternative requirements in Listing Rule 5550(b).
-
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
3/25/2024
Aquestive Therapeutics, Inc. today announced the closing of its previously announced underwritten public offering of 16,666,667 shares of its common stock at the public offering price of $4.50 per share.
-
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
3/22/2024
Sangamo Therapeutics, Inc. today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase and sale of an aggregate of 24,761,905 shares of its common stock.
-
XOMA Declares Quarterly Preferred Stock Dividends - March 21, 2024
3/21/2024
XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock.
-
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/20/2024
Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that the Compensation Committee of the Board of Directors approved certain equity awards to the Company’s new President and Chief Executive Officer, Steven Lo, effective March 18, 2024.
-
Delcath Systems Closes $7 Million Private Placement
3/20/2024
Delcath Systems, Inc. confirmed the closing of the previously announced private placement with certain accredited investors comprised of existing investors.